Ultimovacs ASA (ULTI.OL)
NOK 2.05
(0.0%)
NOK 2.05
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -215.73 Million NOK | -17.48% |
| 2022 | -183.63 Million NOK | -12.08% |
| 2021 | -163.83 Million NOK | -31.97% |
| 2020 | -124.14 Million NOK | -101.54% |
| 2019 | -61.6 Million NOK | -8.98% |
| 2018 | -56.52 Million NOK | -69.27% |
| 2017 | -33.39 Million NOK | -14.42% |
| 2016 | -29.18 Million NOK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -28.64 Million NOK | 57.68% |
| 2024 Q2 | -45.84 Million NOK | -60.01% |
| 2023 Q1 | -50.76 Million NOK | 29.74% |
| 2023 Q4 | -67.69 Million NOK | -23.75% |
| 2023 Q3 | -54.7 Million NOK | -8.03% |
| 2023 Q2 | -50.64 Million NOK | 0.24% |
| 2023 FY | -225.94 Million NOK | -23.04% |
| 2022 Q2 | -35.42 Million NOK | -11.04% |
| 2022 Q1 | -31.9 Million NOK | 37.36% |
| 2022 FY | -183.63 Million NOK | -12.08% |
| 2022 Q4 | -72.25 Million NOK | -64.01% |
| 2022 Q3 | -44.05 Million NOK | -24.38% |
| 2021 Q1 | -31.21 Million NOK | -21.99% |
| 2021 FY | -163.83 Million NOK | -31.97% |
| 2021 Q4 | -50.92 Million NOK | -19.79% |
| 2021 Q2 | -39.17 Million NOK | -25.49% |
| 2021 Q3 | -42.51 Million NOK | -8.54% |
| 2020 Q4 | -25.58 Million NOK | 17.77% |
| 2020 Q1 | -31.25 Million NOK | -34.64% |
| 2020 Q2 | -36.18 Million NOK | -15.75% |
| 2020 Q3 | -31.11 Million NOK | 14.0% |
| 2020 FY | -124.14 Million NOK | -101.54% |
| 2019 Q1 | -14.97 Million NOK | -11.2% |
| 2019 FY | -61.6 Million NOK | -8.98% |
| 2019 Q4 | -23.21 Million NOK | -20.18% |
| 2019 Q3 | -19.31 Million NOK | -371.61% |
| 2019 Q2 | -4.09 Million NOK | 72.64% |
| 2018 Q1 | -10.96 Million NOK | -39.05% |
| 2018 FY | -56.52 Million NOK | -69.27% |
| 2018 Q4 | -13.46 Million NOK | 21.66% |
| 2018 Q3 | -17.18 Million NOK | -15.27% |
| 2018 Q2 | -14.9 Million NOK | -35.94% |
| 2017 Q1 | -8.8 Million NOK | 0.0% |
| 2017 Q2 | -8.21 Million NOK | 6.67% |
| 2017 Q4 | -7.88 Million NOK | 6.98% |
| 2017 Q3 | -8.47 Million NOK | -3.16% |
| 2017 FY | -33.39 Million NOK | -14.42% |
| 2016 FY | -29.18 Million NOK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arctic Bioscience AS | -48.58 Million NOK | -344.028% |
| Aqua Bio Technology ASA | -17.85 Million NOK | -1108.121% |
| ArcticZymes Technologies ASA | 15.74 Million NOK | 1470.1% |
| BerGenBio ASA | -191.81 Million NOK | -12.469% |
| Hofseth BioCare ASA | -102.52 Million NOK | -110.415% |
| PCI Biotech Holding ASA | -22.24 Million NOK | -869.992% |
| Thor Medical ASA | -7.16 Million NOK | -2913.073% |